Oestrogen and progesterone receptors in ovarian carcinoma

Endocrine-Related Cancer

Volumn 5, Issue 4, 1998, Pages 293-301

  Scambia, G ^a   Ferrandina, G ^a   D'Agostino, G ^a   Fagotti, A ^a   Di Stefano, M ^a   Fanfani, F ^a   Serri, F G ^a   Mancuso, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

CANCER PATIENT; CANCER SURVIVAL; DRUG RECEPTOR BINDING; HORMONAL REGULATION; HORMONAL THERAPY; OVARY CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

EID: 0032430453     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0050293     Document Type: Review

References (75)

1. Agarwal N, Rao DL, Murgennnshan K, Verma U, Mittal S, Buckshee K & Chapeker TN 1987 Clinical evaluation of steroid receptors in ovarian neoplasms. International Journal of Gynecology and Obstetrics 25 145-149.
2. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich J, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D & Fryer JG 1993 Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the mid-Atlantic oncology program. Journal of Clinical Oncology 10 1957-1968.
3. Anderl P, Fuith LC, Daxenbichler G, Marth C & Dapunt O 1988 Correlation between steroid hormone receptors, histological and clinical parameters in ovarian carcinoma. Gynaecologic and Obstetric Investigation 25 135-140.
4. Bergqvist A, Kullander S & Thorell J 1981 A study of estrogen and progesterone cytosol receptor concentration in benign and malignant ovarian tumors and a review of malignant ovarian tumors treated with medroxy-progesterone acetate. Acta Obstetrica et Gynecologica Scandinavica (Suppl) 101 75-81.
5. Bizzi A, Codegoni AM, Landoni F, Marelli G, Marsoni S, Spina AM, Torri W & Mangioni C 1988 Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival. Cancer Research 48 6222-6226.
6. Campbell JJ, Rome RM, Quinn MA et al. 1985 Tamoxifen for recurrent progressive epithelial ovarian tumors. Medical and Pediatric Oncology 13 150-151.
7. Casagrande JT, Lovie EW, Pike MC, Roy S, Ross RK & Henderson BE 1979 Incessant ovulation and ovarian cancer. Lancet ii 170-172.
8. Copeland LJ & Gershenson DM 1986 Ovarian cancer recurrences in patients with no macroscopic tumor at second look laparotomy. Obstetrics and Gynecology 68 873-874.
9. Cramer DW & Welch WR 1983 Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. Journal of the National Cancer Institute 71 717-721.
10. Creasman WT, McCarty KS & Barton TK 1980 Clinical correlates of estrogen and progesterone binding proteins in human endometrial adenocarcinoma. Obstetrics and Gynecology 55 63-68.
11. Creasman WT, Sasso RA, Weed JC & McCarty KS 1981 Ovarian carcinoma: histologic and clinical correlation of cytoplasmic estrogen and progesterone binding. Gynecology and Oncology 12 319-327.
12. European Organization for Research and Treatment of Cancer. Breast Cancer Cooperative Group 1980 Revision of the standards for the assessment of hormone receptors in human breast cancer. European Journal of Cancer 16 1513-1515.
13. Fathalla MF 1971 Incessant ovulation - a factor in ovarian neoplasia. Lancet 2 163.
14. Ford LC, Berek JS, Lagasse LD, Hacker NF, Heins Y, Esmailian F, Leuchter RS & DeLange RJ 1983 Estrogen and progesterone receptors in ovarian neoplasm. Gynaecologic Oncology 15 299-304.
15. Galtier-Dereure F, Capony F, Maudelonde T & Rochefort H 1992 Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. Journal of Clinical Endocrinology and Metabolism 75 1497-1502.
16. Geisinger KR, Berens ME, Duckett Y et al. 1990 The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro. Cancer 65 1055-1061.
17. Geisler HE 1983 Megestrol acetate for the palliation of advanced ovarian carcinoma. Obstetrics and Gynecology 61 95-98.
18. Geisler HE 1985 The use of high-dose megestrol acetate in the treatment of ovarian adenocarcinoma. Seminars in Oncology 12 20-22.
19. Geisler JP, Wiemann MC, Miller GA, Zhou Z & Geisler HE 1995 Estrogen and progesterone receptors in malignant mixed mesodermal tumors of the ovary. Journal of Surgical Oncology 59 45-47.
20. Geisler JP, Wiemann MC, Miller GA & Geisler HE 1996 Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cyst adenocarcinoma of the ovary. Gynecologic Oncology 60 424-427.
21. Gronroos M, Kangas L, Maenpa D, VanHaranta R, Nieminen A & Johansson R 1984 Steroid receptors and response of ovarian cancer to hormones in vitro. British Journal of Obstetrics and Gynaecology 91 472-478.
22. Hamerlynck JVThH, Maskens AP, Mangioni C et al. 1985a Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: An EORTC Gynecologic Cancer Cooperative Group study. Gynecologic Oncology 22 313-316.
23. Hamerlynck JVTH, Vermorken JB, van der Burg MEL et al. 1985b Phase II study of Tamoxifen in advanced ovarian cancer. Proceedings opf the Third European Conference on Clinical Oncology 73 (abstract).
24. Hamilton TC, Davies P & Griffiths K 1981 Androgen and oestrogen binding in cytosols of human ovarian tumours. Journal of Endocrinology 90 421-431.
25. Harding M, Cowan S, Hole D, Classidy L, Kitchener H, Davis J & Leake R 1990 Estrogen and progesterone receptors in ovarian cancer. Cancer 65 486-491.
26. Hatch KD, Becham JB, Blessing JA & Creasman WT 1991 Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group Study of second-line therapy in 105 patients. Cancer 68 269-271.
27. Hoover R, Gray LA & Fraumeni JF Jr 1977 Stilboestrol (diethylstilbestrol) and the risk of ovarian cancer. Lancet ii 533-534.
28. Iversen OE, Skaarland E & Utaaker E 1986 Steroid receptor content in human ovarian tumors: survival of patients with ovarian carcinoma related to steroid receptor content. Gynaecologic Oncology 23 65-76.
29. Jabara AG 1962 Induction of canine ovarian tumors by diethylstilbestrol and progesterone. Australian Journal of Experimental Biology 40 139-152.
30. Jakobsen A, Hansen V & Poulsen HS 1988 DNA-profile and steroid receptor content of human ovarian cancer. European Journal of Gynaecological Oncology 9 461-463.
31. Jolles B 1962 Progesterone in the treatment of advanced malignant tumors of breast, ovary, and uterus. British Journal of Cancer 16 209-221.
32. Joly DJ, Lilenfeld AM, Diamond EL & Bross I 1974 An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. American Journal of Epidemiology 99 190-209.
33. Jones LA, Edwards C, Freedman RS, Tan MT & Gallager HS 1983 Estrogen and progesterone receptor titers in primary epithelial ovarian carcinomas. International Journal of Cancer 32 567-571.
34. Kauppila A, Vierikko P, Kivinen S, Stenback F & Vihko R 1983 Clinical significance of estrogen and progestin receptors in ovarian cancer. Obstetrics and Gynecology 61 320-326.
35. Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W & Pfleiderer A 1992 Steroid receptors in ovarian carcinoma: immunohistochemical determinatin may lead to new aspects. Gynecology and Oncology 47 317-322.
36. Kuhnel R, Delemare JFM, Rao BR & Stolk JG 1987 Correlation of multiple steroid receptors with histological type and grade in human ovarian cancer. International Journal of Gynecological Pathology 6 248-256.
37. Langdon SP, Hawkes MM, Lawrie SS, Hawkins RA, Tesdale AL, Crew AJ, Miller WR & Smyth JF 1990 Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. British Journal of Cancer 62 213-216.
38. Langdon SP, Ritchie A, Young K, Crew AJ, Sweeting V, Bramley T, Hillier S, Hawkins RA, Tesdale AL, Smyth JF & Miller WR 1993 Contrasting effects on 17β-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo. International Journal of Cancer 55 459-464.
39. Langdon SP, Hirst GL, Miller EP, Hawkins A, Tesdale AL, Smyth JF & Miller WR 1994 The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. Journal of Steroid Biochemistry and Molecular Biology 50 131-135.
40. Lantta M 1984 Estradiol and progesterone receptors in normal ovary and ovarian tumors. Acta Obstetrica et Gynecologica Scandinavica 63 497-503.
41. McGowan L, Parent L, Lednar W & Norris HJ 1979 The woman at risk for developing ovarian cancer. Gynecology and Oncology 7 325-344.
42. McGuire WL 1978 Steroid receptors in human breast cancer. Cancer Research 38 4289-4291.
43. Malkasian GD Jr, Decker DG, Jorgensen EO et al. 1973 6-dehydro-6,17α-dimethylprogesterone (NSC-123018) for the treatment of metastatic and recurrent ovarian carcinoma. Cancer Chemotherapy Reports 57 241-242.
44. Malkasian GD Jr, Decker DG, Jorgensen EO & Edmonson JH 1977 Medroxyprogesterone acetate for the treatment of metastatic and recurrent ovarian cancer. Cancer Treatment Reports 61 913-914.
45. Mangioni C, Franceschi S, La Vecchia G et al. 1981 High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemptherapy. Gynecologic Oncology 12 314-318.
46. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W & Dubeshter B 1996 Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecology and Oncology 62 4-6.
47. Masood S, Heitmann J, Nuss RC & Benrubi GI 1989 Clinical correlation of hormone receptor status in epithelial ovarian cancer. Gynecology and Oncology 34 57-60.
48. Myers AM, Moore GE & Major FJ 1981 Advanced ovarian carcinoma: response to antioestrogen therapy. Cancer 48 2368-2370.
49. Nash JD, Ozols RF, Smyth JF & Hamilton TC 1989 Estrogen and antiestrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstetrics and Gynaecology 73 1009-1016.
50. 3H-R5020 binding in cytosols of normal and neoplastic human ovarian tissue. International Journal of Cancer 31 603-608.
51. Press MF, Nousek-Goebl N, King WJ, Herbst AL, GReene GL 1985 Immunohistochemical assessment of estrogen receptor in ovarian carcinoma. Localization with monoclonal etrophilin antibodies compared with biochemical assays. Laboratory Investigation 53 349-361.
52. Quinn MA, Pearce P, Rome R, Funder JV, Fortune D & Pepperell RJ 1982 Cytoplasmic steroid receptors in ovarian tumours. British Journal of Obstetrics and Gynaecology 89 754-759.
53. Quinn MA, Rome RM, Cauchi M & Fortune DW 1988 Steroid receptors and ovarian tumors: variation within primary tumors and between primary tumors and metastases. Gynecology and Oncology 31 424-429.
54. Richman CM, Holt JA, Lorinez MA & Herbst AL 1985 Persistence and distribution of estrogen receptor in advanced epithelial ovarian carcinoma after chemotherapy. Obstetrics and Gynecology 65 257-263.
55. Rose P, Reale FR, Longcope C & Hunter R 1990 Prognostic significance of oestrogen and progesterone receptors in epithelial ovarian cancer. Obstetrics and Gynecology 76 258-263.
56. Runge HM, Neumann HA, Bauknecht T & Pfleiderer A 1986 Growth patterns and hormonal sensitivity of primary tumour, abdominal metastasis and ascitic fluid from human epithelial ovarian carcinomas in the tumour colony-forming assay. European Journal of Cancer and Clinical Oncology 22 691-696.
57. Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, De Vincenzo R, Bonanno G, Ferrandina G, Isola G & Mancuso S 1992 Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours. European Journal of Cancer 28 1885-1889.
58. Scambia G, Benedetti-Panici P, Ferrandina G, Di Stefano M, Salerno G, Romanini ME, Fagotti A & Mancuso S 1995 Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. British Journal of Cancer 72 361-366.
59. Schwartz PE, Keating G, MacLusky N, Naftolin F & Eisenfeld A 1982 Tamoxifen therapy for advanced ovarian cancer. Obstetrics and Gynecology 59 583-588.
60. Schwartz PE, Merino MJ, LiVolsi VA, Lawrence R, MacLusky N & Eisenfeld A 1985 Histopathologic correlation of estrogen and progestin receptor protein in epithelial ovarian carcinomas. Obstetrics and Gynecology 66 428-433.
61. Schwartz PE, Maclusky N, Merino MJ, Livols VA, Kohorn E & Eisenfeld A 1986 Are cytosol estrogen and progestin receptors of prognostic significance in the management of epithelial ovarian cancers? Obstetrics and Gynecology 68 751-758.
62. Schwartz PE, Chambers JT & Kohorn EI 1989 Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. Cancer 63 1074-1079.
63. Sevelda P, Denison U, Schemper M, Spona J, Vavra N & Salzer H 1990 Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. British Journal of Obstetrics and Gynecology 97 706-712.
64. Sikic BI, Scudder SA, Ballon SC et al. 1986 High-dose megestrol acetate therapy of ovarian carcinoma: A phase II study by the Northern California Oncology Group. Seminars in Oncology 4 26-32.
65. Slevin ML, Harvey VJ, Osborne RJ et al. 1986 A phase II study of tamoxifen in ovarian carcinoma. European Journal of Cancer and Clinical Oncology 22 309-312.
66. Slotman BJ, Kuhnel R, Rao BR, Dijkhuizen GH, deGraaff J & Stolk JG 1989 Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival. Gynecology and Oncology 33 76-81.
67. Slotman BJ, Nauta JJP & Ramanath BR 1990 Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer 66 740-744.
68. Spona J, Gitsch E, Salzer H & Karrer K 1983 Estrogen and gestagen receptors in ovarian carcinoma. Gynecologic and Obstetric Investigation 16 189-198.
69. Sutton GP, Senior MB, Strauss JF & Mikuta JJ 1986 Estrogen and progesterone receptors in epithelial ovarian malignancies. Gynecology and Oncology 23 176-182.
70. Toppila M, Tyler JPP, Fay R, Baird PJ, Craindon AJ, Eastman CJ & Hudson CN 1986 Steroid receptors in human ovarian malignancy. A review of four years tissue collection. British Journal of Obstetrics and Gynaecology 93 986-992.
71. Vierikko P, Kauppila A & Vihko R 1983 Cytosol and nuclear estrogen and progestin receptors and 17β-hydroxy-steroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumours of the human ovary. International Journal of Cancer 32 413-422.
72. Vihko R, Isotalo H, Kauppila H & Vierikko P 1983 Female sex steroid receptors in gynecological malignancies: clinical correlates. Journal of Steroid Biochemistry 19 827-832.
73. Ward HWC 1972 Progestogen therapy for ovarian carcinoma. Journal of Obstetrics and Gynecology 79 555-559.
74. Weiner SA, Alberts DS, Surwit EA, Davis J & Grosso D 1987 Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecology and Oncology 27 208-213.
75. Willcocks D, Toppila M, Hudson CN, Tyler JJP, Baird PJ & Eastman PJ 1983 Estrogen and progesterone receptors in human ovarian tumors. Gynaecologic Oncology 16 246-253.